📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Dynavax

1.1 - Company Overview

Dynavax Logo

Dynavax

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of biopharmaceutical products to prevent infectious diseases, including HEPLISAV-B, an adult hepatitis B vaccine designed to prevent infection by all known subtypes of the virus, and CpG 1018, an adjuvant used in vaccines to enhance the immune response and contained in the HEPLISAV-B hepatitis B vaccine.

Products and services

  • CpG 1018: Immune-enhancing adjuvant used in vaccines, included in HEPLISAV-B to boost responses conferring adult hepatitis B protection against all known viral subtypes
  • HEPLISAV-B: Adjuvanted hepatitis B vaccine for adults, employing CpG 1018 to enhance immune response and prevent infection across all known HBV subtypes
  • Infectious Disease Product R&D: Biopharmaceutical research program discovering and developing novel products to prevent and treat infectious diseases, encompassing vaccines and adjuvants as therapeutic and preventive products

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Dynavax

Agenus Logo

Agenus

HQ: United States Website
  • Description: Provider of immunotherapies and vaccines for cancer and infectious diseases, advancing antibodies that activate antitumor immunity: botensilimab (CTLA-4; Phase 2 in melanoma, MSS colorectal and pancreatic cancers), balstilimab (PD-1; backbone for combinations), zalifrelimab (CTLA-4), AGEN2373 (CD137 agonist), AGEN1571 (ILT-2 antagonist), and an anti-ILT4 antagonist developed with pembrolizumab and chemotherapy.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Agenus company profile →
Adaptate Biotherapeutics Logo

Adaptate Biotherapeutics

HQ: Canada Website
  • Description: Provider of antibodies designed to modulate gamma delta T cells in situ.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Adaptate Biotherapeutics company profile →
Inhibrx Logo

Inhibrx

HQ: United States Website
  • Description: Provider of clinical-stage biopharmaceutical research and development, advancing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Utilizes diverse protein engineering methods, including proprietary approaches, to address complex target and disease biology.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Inhibrx company profile →
Tizona Therapeutics Logo

Tizona Therapeutics

HQ: United States Website
  • Description: Provider of next-generation immunotherapies, including TTX-080, an investigational antibody targeting HLA-G evaluated as monotherapy and in combination in patients with advanced cancers; TTX-030, a monoclonal antibody inhibiting CD39 studied with an approved anti-PD-1 agent and standard chemotherapy in adults with advanced cancer; and TZ-040, a pre-clinical program anticipated to enter IND-enabling studies targeting novel immuno-modulatory molecules.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Tizona Therapeutics company profile →
Xenikos Logo

Xenikos

HQ: The Netherlands Website
  • Description: Provider of antibody-based immunotherapies, developing a combination of two toxin-loaded anti-T-cell antibodies to quickly reset the immune system in patients with serious immune diseases or transplant rejection.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Xenikos company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Dynavax

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Dynavax

2.2 - Growth funds investing in similar companies to Dynavax

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Dynavax

4.2 - Public trading comparable groups for Dynavax

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Dynavax

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Dynavax

What does Dynavax do?

Dynavax is a provider of biopharmaceutical products to prevent infectious diseases, including HEPLISAV-B, an adult hepatitis B vaccine designed to prevent infection by all known subtypes of the virus, and CpG 1018, an adjuvant used in vaccines to enhance the immune response and contained in the HEPLISAV-B hepatitis B vaccine.

Who are Dynavax's competitors?

Dynavax's competitors and similar companies include Agenus, Adaptate Biotherapeutics, Inhibrx, Tizona Therapeutics, and Xenikos.

Where is Dynavax headquartered?

Dynavax is headquartered in United States.

How many employees does Dynavax have?

Dynavax has 1,000 employees 🔒.

When was Dynavax founded?

Dynavax was founded in 2010 🔒.

What sector and industry vertical is Dynavax in?

Dynavax is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Dynavax

Who are the top strategic acquirers in Dynavax's sector and industry

Top strategic M&A buyers and acquirers in Dynavax's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Dynavax?

Top strategic M&A buyers groups and sectors for Dynavax include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Dynavax's sector and industry vertical

Which are the top PE firms investing in Dynavax's sector and industry vertical?

Top PE firms investing in Dynavax's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Dynavax's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Dynavax's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Dynavax's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Dynavax include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Dynavax's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Dynavax?

The key public trading comparables and valuation benchmarks for Dynavax include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Dynavax for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Dynavax with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Dynavax's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Dynavax with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Dynavax's' sector and industry vertical?

Access recent funding rounds and capital raises in Dynavax's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Dynavax